UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

(Mark One)


	X	QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: ~~December~~March 31, ~~2015~~2016


		TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______________.to _______________.

Commission File Number: 000-53306

UV FLU TECHNOLOGIES, INC.

(Exact name of registrant as specified in its charter)


Nevada			46-5559864
(State or Other Jurisdiction of			(I.R.S. Employer
Incorporation or Organization)			Identification Number)
250 Parkway Dr. Suite 150 Lincolnshire, Illinois 60069
(Address of principal executive offices) (Zip Code)
(847) 831-2428
(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act: NONE

Securities registered pursuant to Section 12(g) of the Act: Common Stock

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No X

Indicate by check mark whether the Registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit and post such files). Yes X No 

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):


	Large accelerated filer 	Accelerated filer 

	Non-accelerated filer  (Do not check if a smaller reporting company)	Smaller reporting company X

Indicate by check mark whether the Registrant is a shell company (as defined by Rule 12b-2 of the Act). Yes  No X

As of ~~May~~June 1115, 2016, there were 134,164,028 shares of the Registrant's common stock outstanding at par value of $0.001 per share.

UV FLU TECHNOLOGIES, INC.

FORM 10-Q

~~December~~March 31, ~~2015~~2016

INDEX

	PAGE
PART I—FINANCIAL INFORMATION
Item 1. Consolidated Financial Statements	3-12
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	13-15
Item 3. Quantitative and Qualitative Disclosures About Market Risk	15
Item 4. Controls and Procedures	15-16
PART II—OTHER INFORMATION
Item 1. Legal Proceedings	17
Item 1A. Risk Factors	17
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	17
Item 3. Defaults Upon Senior Securities	17
Item 4. Mine Safety Disclosures	17
Item 5. Other Information	17
Item 6. Exhibits	17
Signatures	18


	PAGE
PART I—FINANCIAL INFORMATION

Item 1. Consolidated Financial Statements	3

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	14

Item 3. Quantitative and Qualitative Disclosures About Market Risk	17

Item 4. Controls and Procedures	17

PART II—OTHER INFORMATION

Item 1. Legal Proceedings	18

Item 1A. Risk Factors	18

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	18

Item 3. Defaults Upon Senior Securities	18

Item 4. Mine Safety Disclosures	18

Item 5. Other Information	18

Item 6. Exhibits	18

Signatures	19

PART I—FINANCIAL INFORMATION

Item 1. Consolidated Financial Statements.

UV FLU TECHNOLOGIES, INC

CONDENSED CONSOLIDATED BALANCE SHEETS

		December 31,		September 30,
		March 31,		September 30,
		2015		2015
		2016		2015
ASSETS		(~~Unaudited~~unaudited)
Current assets:
Cash	$	213,~~238~~282	$	12,787
Accounts receivable, net		~~100~~60,~~506~~269		40,976
Inventories		4367,~~030~~154		73,379
Prepaid expenses and other current assets		2156,~~704~~810		9,563
Total current assets		~~186~~187,~~478~~515		136,705
Property and equipment, net		2725,~~635~~617		29,651
Total assets	$	~~214~~213,~~113~~132	$	166,356
LIABILITIES AND STOCKHOLDERS' DEFICIT
Current liabilities:
Accounts payable and accrued expenses	$	~~433~~536,~~711~~759	$	535,071
Current portion of debt obligations		233,~~277~~278		314,777
Total current liabilities		~~666~~770,~~988~~037		849,848
Long term liabilities:
Debt obligations, net of current portion		13,854		-
Total liabilities		~~680~~783,~~842~~891		849,848
Stockholders' deficit:
Common stock, par value $0.001 per share, 150,000,000 shares authorized, and		132,731		84,968
132,260,678 and 84,968,333 shares outstanding at December 31, 2015 and
132,730,066 and 84,968,333 shares outstanding at March 31, 2016 and September 30, 2015, respectively
September 30, 2015, respectively		132,261		84,968
Common stock subscribed but unissued		18,000		519,594
Additional paid-in capital		4,~~807~~818,~~934~~964		3,964,409
Accumulated deficit		(5,~~424~~540,~~924~~454)		(5,252,463)
Total stockholders' deficit		(~~466~~570,~~729~~759)		(683,492)
Total liabilities and stockholders' deficit	$	~~214~~213,~~113~~132	$	166,356

See accompanying notes to the condensed consolidated financial statements

UV FLU TECHNOLOGIES, INC

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

		Three months ended December 31,
		Three months ended March 31,
		2015		2014
		2016		2015
Net sales	$	6652,~~651~~976	$	3465,~~533~~860
Cost of sales		3726,~~196~~927		2449,~~902~~638
Gross profit		2926,~~455~~049		916,~~631~~222
Operating expenses:
General and administrative		~~171~~115,~~163~~324		~~377~~136,~~941~~495
Loss from operations		(~~141~~89,~~708~~275)		(~~368~~120,~~310~~273)
Other income (expense):
Interest expense		(3026,~~753~~257)		(1226,~~408~~727)
Change in fair value of derivative liabilities		-		43,503
Total other income (expense), net		(26,257)		(26,727)
Total other income (expense), net		(30,753)		31,095
Net loss	$	(115,532)	$	(147,000)
Net loss	$	(172,461)	$	(337,215)
Net loss per share - basic and diluted	$	(0.00)	$	(0.00)
Weighted average number of common shares outstanding - basic and diluted		~~102~~132,~~584~~693,~~833~~959		7582,~~068~~886,~~133~~552

See accompanying notes to the condensed consolidated financial statements

UV FLU TECHNOLOGIES, INC

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS


		Six months ended March 31,
		2016		2015
Net sales	$	119,627	$	100,393
Cost of sales		64,123		74,540
Gross profit		55,504		25,853

Operating expenses:
General and administrative		286,485		514,436
Loss from operations		(230,981)		(488,583)

Other income (expense):
Interest expense		(57,010)		(39,135)
Change in fair value of derivative liabilities		-		43,503
Total other income (expense), net		(57,010)		4,368

Net loss	$	(287,991)	$	(484,215)

Net loss per share - basic and diluted	$	(0.00)	$	(0.01)

Weighted average number of common shares outstanding - basic and diluted		118,236,496		78,934,384

See accompanying notes to the condensed consolidated financial statements

UV FLU TECHNOLOGIES, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

		Three months ended December 31,
		Six months ended March 31,
CASH FLOWS FROM OPERATING ACTIVITIES:		~~2015~~2016		~~2014~~2015
Net loss	$	(~~172~~287,~~461~~991)	$	(~~337~~484,215)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation		24,~~016~~034		46,~~875~~892
Stock-based compensation expense		-		6,630
Shares issued for compensation		2334,~~000~~500		-
Shares issued for services		25,000		-
Shares issued for interest		19,262		239,450
Change in fair value of derivative liabilities		-		(43,503)
Interest expense for settlement of accrued interest		-		17,700
Change in operating assets and liabilities
Accounts receivable		(5919,~~530~~293)		(3051,~~879~~856)
Inventories		306,~~349~~225		3290,~~037~~270
Prepaid expenses and other current assets		(1247,~~141~~247)		~~625~~(2,514)
Accounts payable and accrued expenses		~~(16~~86,~~788)~~261		~~363~~219,~~162~~315
Net cash used in operating activities		(~~161~~179,~~293~~249)		(41,~~268~~831)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from debt obligations		13,854		-
Payments on debt obligations		-		(363)
Proceeds from common stock subscribed but unissued		18,000		-
Proceeds from sale of common stock		137,890		-
Net cash provided by (used in) financing activities		169,744		(363)
Net change in cash		8(9,~~451~~505)		(42,~~631~~194)
Cash, beginning of period		12,787		4,748
Cash, end of period	$	213,~~238~~282	$	~~117~~2,554
Supplemental disclosures of non-cash financing activities:
		-
Supplemental disclosures of non-cash investing and financing activities:
Issuance of common stock for debt obligations and accrued interest	$	102,572	$	-
Issuance of common stock for accounts payable	$	63,500	$	-
Stock subscribed but unissued	$	-	$	83282,594
Issuance of previously subscribed common stock	$	519,594	$	30,000
Reclassification of derivative liabilities to equity	$	519,594	$	170,340
Reclassification of derivative liability to equity	$	-	$	170,340
Issuance of previously subscribed common stock	$	-	$	30,000

See accompanying notes to the condensed consolidated financial statements

~~1. DESCRIPTION~~NOTES OFTO ~~BUSINESS~~CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

MARCH 31, 2016

DESCRIPTION OF BUSINESS

UV Flu Technologies, Inc. (referred to herein as “Company” “we”, “us”, “our” and similar terms) was incorporated as Northwest Chariots Incorporated in the State of Nevada, United States of America, on April 4, 2006. On November 12, 2009, the Company changed its name from Northwest Chariots Incorporated to UV Flu Technologies, Inc. (“UV Flu”). The Company’s fiscal year end is September 30. We acquired our subsidiary, RxAir Industries, LLC (“RxAir”), on January 31, 2011.

GOING CONCERN

The Company’s unaudited condensed consolidated financial statements are prepared using the accrual method of accounting in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities in the normal course of business. The Company has had recurring losses from operations, has negative operating cash flows during the period ended ~~December~~March 31, ~~2015~~2016 and has an accumulated deficit of ($5,~~424~~540,~~924~~454) as of ~~December~~March 31, ~~2015~~2016. These factors raise substantial doubt about the Company’s ability to continue as a going concern for a reasonable period of time. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable. If the Company is unable to obtain adequate capital, it could be forced to cease or reduce its operations.

In order to continue as a going concern, the Company will need, among other things, additional capital resources. The Company will need to continue to raise funds through the sale of its equity securities to obtain additional operating capital. The Company is dependent upon its ability, and will continue to attempt, to secure additional equity and/or debt financing until the Company can earn revenue and realize positive cash flow from its operations. There are no assurances that the Company will be successful in earning revenue and realizing positive cash flow from its operations. Without sufficient financing it is unlikely that the Company will continue as a going concern. These condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classification of liabilities that might result from this uncertainty.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The included (a) condensed consolidated balance sheet as of December 31, 2015, which has been derived from audited financial statements, and (b) the unaudited condensed consolidated financial statements as of March 31, 2016 and 2015 of the Company presented herein have been prepared pursuant to the rules of the Securities and Exchange Commission (“SEC”) for quarterly reports on Form 10-Q and do not include all of the information and footnotes required by GAAP. These unaudited condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements and notes thereto included in our Report on Form 10-K for our fiscal year ended September 30, 2015.

In the opinion of management, the interim condensed consolidated financial statements reflect all adjustments of a normal recurring nature necessary for a fair presentation of the results for the interim period presented. Operating results for the three~~-month~~ and six period ended ~~December~~March 31, ~~2015~~2016 are not necessarily indicative of the results that may be expected for the year ending September 30, 2016.

Principles of Consolidation

The unaudited condensed consolidated financial statements contain the accounts and activities of UV Flu and RxAir. All significant intercompany accounts and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of net sales and expenses during the reporting period. By their nature, these estimates and assumptions are subject to an inherent degree of uncertainty. Significant estimates made by management include, among others, provisions for uncollectible receivables and sales returns, warranty liabilities, valuation of inventories, fair value of financial instruments, recoverability of long-lived assets, and valuation of stock-based transactions and realization of deferred tax assets. The Company bases its estimates on historical experience, knowledge of current conditions and the Company’s belief of what could occur in the future considering available information. The Company reviews its estimates on an on-going basis. The actual results experienced by the Company may differ materially and adversely from its estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.

Revenue Recognition

The Company recognizes revenue when earned and related costs of sales and expenses when incurred. The Company recognizes revenue in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 605. ASC Topic 605 requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services rendered; (3) the fee is fixed and determinable; and (4) collectability is reasonably assured. Cost of revenue consists of the cost of the purchased goods and labor related to the corresponding sales transaction. When a right of return exists, the Company defers revenues until the right of return expires. Revenues are recognized only when the Company has transferred to the customer the significant risk and rewards of ownership of the goods, title to the products transfers, the amount is fixed and determinable, evidence of an agreement exists, there is reasonable assurance of collection of the sales proceeds, the Company has no future obligations, and the customer bears the risk of loss. This occurs at the time of shipment (FOB shipping point) of the products from the Company’s warehouse and an invoice is prepared. There are no rights of return and exchange is allowed only on defective products. Recognition of revenue is not affected as the right of exchange results in new units being shipped to the customer once defective units have been received by the company and verified as defective.

Reclassifications

Certain reclassifications have been made to the 2015 condensed interim financial statements to conform to the 2016 condensed interim consolidated financial statements presentation. The reclassifications had no effect on net loss or cash flows as previously stated.

Fair Value of Financial Instruments

The Company’s financial instruments consist principally of cash, accounts receivable, and accounts payable and accrued expenses and debt instruments. The Company believes that the carrying values of all financial instruments, approximate their current fair values due to their nature and respective durations.

Credit Risks

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash deposits and accounts receivable. Cash deposits at each financial institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. The Company does not have funds in excess of the FDIC insured limits.

The Company’s trade accounts receivable are primarily derived from sales to one customer. The Company performs credit evaluations of its customers’ financial condition and limits the amount of credit extended when deemed necessary, but generally requires no collateral. The Company believes that the concentration of credit risk in its trade receivables is moderated by its credit evaluation process, relatively short collection terms and the high level of credit worthiness of its customers. Reserves are maintained for potential credit losses, and such losses historically have not been significant and have been within management’s expectations.

Concentrations

The Company’s accounts receivable as of ~~December~~March 31, ~~2015~~2016 was concentrated with ~~one~~four ~~customer~~customers, representing 87% of gross receivables. A significant reduction in sales to, or the inability to collect receivables from, a significant customer could have a material adverse impact on the Company.

For the three months ended ~~December~~March 31, ~~2015,~~2016 ~~two~~and ~~customers~~2015 ~~made~~four upand ~~85% of our net sales. For the~~ three ~~months~~customers ~~ended~~accounted ~~December~~for ~~31,~~87% ~~2014,~~and ~~one customer represented 85~~90% of our ~~net~~gross sales, respectively.

For the six months ended March 31, 2016 and 2016 four and two customers accounted for 87% and 60% of our gross sales, respectively.

Inventories

Inventories are stated at the lower of cost or market, with cost being determined using the first-in first-out method all of which are classified as finished goods.

Property and Equipment

Property and equipment are recorded at cost. Expenditures for major additions and improvements are capitalized and minor replacements, maintenance, and repairs are charged to expense as incurred. When property and equipment are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations for the respective period. Depreciation is provided over the estimated useful lives of the related assets using the straight-line method for financial statement purposes. The estimated useful live for equipment is five years.

7The Company reviews the carrying value of property and equipment for impairment whenever events and circumstances indicate that the carrying value of an asset may not be recoverable from the estimated future cash flows expected to result from its use and eventual disposition. In cases where undiscounted expected future cash flows are less than the carrying value, an impairment loss is recognized equal to an amount by which the carrying value exceeds the fair value of assets. The factors considered by management in performing this assessment include current operating results, trends and prospects, the manner in which the property is used, and the effects of obsolescence, demand, competition, and other economic factors. Based on this assessment there were no impairments needed as of March 31, 2016.

The Company reviews the carrying value of property and equipment for impairment whenever events and circumstances indicate that the carrying value of an asset may not be recoverable from the estimated future cash flows expected to result from its use and eventual disposition. In cases where undiscounted expected future cash flows are less than the carrying value, an impairment loss is recognized equal to an amount by which the carrying value exceeds the fair value of assets. The factors considered by management in performing this assessment include current operating results, trends and prospects, the manner in which the property is used, and the effects of obsolescence, demand, competition, and other economic factors. Based on this assessment there were no impairments needed as of December 31, 2015.

Stock-Based Compensation

The Company grants options to purchase the Company’s common stock to employees, directors and consultants under stock option plans. The benefits provided under these plans are stock-based payments that the Company accounts for using the fair value method.

The fair value of each option award is estimated on the date of grant using Black-Scholes that uses assumptions regarding a number of complex and subjective variables. These variables include, but are not limited to, expected stock price volatility, actual and projected employee stock option exercise behaviors, risk-free interest rate and expected dividends. Expected volatilities are based on the historical volatility of the Company’s common stock and other factors. The expected terms of options granted are based on analyses of historical employee termination rates and option exercises. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of the grant. Since the Company does not expect to pay dividends on common stock in the foreseeable future, it estimated the dividend yield to be 0%.

Stock-based compensation expense recognized during a period is based on the value of the portion of stock-based payment awards that is ultimately expected to vest and is amortized under the straight-line attribution method. As stock-based compensation expense is based on awards ultimately expected to vest, it is reduced for estimated forfeitures. The fair value method requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company estimates forfeitures based on historical experience. Changes to the estimated forfeiture rate are accounted for as a cumulative effect of change in the period the change occurred.

Advertising

Advertising costs are expensed as incurred. Advertising costs for the three months ended ~~December~~March 31, ~~2015~~2016 and ~~2014~~2015 were $0 and $63,672, respectively. These costs were included in general and administrative expenses.

Income Taxes

The Company accounts for income taxes and the related accounts under the liability method. Deferred tax assets and liabilities are determined based on the differences between the consolidated financial statement carrying amounts and the income tax bases of assets and liabilities. A valuation allowance is applied against any net deferred tax asset if, based on available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. Therefore, the Company has recorded a full valuation allowance against the net deferred tax assets.

The Company recognizes any uncertain income tax positions on income tax returns at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. There is no unrecognized tax benefits included in the condensed consolidated balance sheet that would, if recognized, affect the effective tax rate.

The Company’s policy is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had $0 accrued for interest and penalties on each of the Company’s condensed consolidated balance sheets at ~~December~~March 31, ~~2015~~2016 and September 30, 2015.

The Company is subject to taxation in the U.S. and various state jurisdictions. Since no tax returns have been filed, all years are subject to examination by the U.S and Illinois tax authorities due to the carry-forward of unaudited net operating losses. The Company does not foresee material changes to its gross uncertain income tax position liability within the next twelve months.

Basic and Diluted Loss Per Share

Basic net loss per share is calculated by dividing net loss by the weighted-average common shares outstanding during the year. Diluted net loss per share is calculated by dividing the net loss by the weighted-average shares and dilutive potential common shares outstanding during the year. Dilutive potential shares consist of dilutive shares issuable upon the exercise of outstanding stock options, warrants using the treasury stock method and convertible debt computed using as-if converted method. In periods of losses, basic and diluted loss per share are the same, as the effect of stock options, warrants and convertible debt on loss per share is anti-dilutive.

Recent Accounting Pronouncements

In May 2014, the FASB and the International Accounting Standards Board jointly issued ASU No. 2014-09, Revenue from Contracts with Customers (“ASU 2014 – 09”), which clarifies the principles for recognizing revenue and develops a common revenue standard for GAAP and International Financial Reporting Standards. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. On July 9, 2015, the FASB approved amendments deferring the effective date by one year to December 15, 2017 for annual reporting periods beginning after that date and permitting early adoption of the standard, but not before the original effective date for reporting periods beginning after December 15, 2016. The Company has not selected a transition method and management has not yet selected a transition method and is currently assessing the impact the adoption of ASU 2014-09 will have on its condensed consolidated financial statements.

In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statement-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern (“ASU 2014 – 15”),, which provides guidance under GAAP about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. In doing so, the amendments should reduce diversity in the timing and content of footnote disclosures. The ASU is effective for all entities and for annual periods ending after December 15, 2016, and interim periods within annual periods beginning after December 15, 2016. Early adoption is permitted. The adoption of ASU 2014-15 is not expected to have a significant impact on the Company’s condensed consolidated financial statements and related disclosures.

In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330) ("ASU 2015-11"). The amendments in ASU 2015-11 require that an entity measure inventory within the scope at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transaction. The amendments in this update more closely align the measurement of inventory in U.S. GAAP with the measurement of inventory in International Financial Reporting. ASU 2015-11 is effective for annual and interim periods beginning on or after December 15, 2016. The amendments in this update should be applied prospectively with early application permitted as of the beginning of the interim or annual reporting period. The Company is currently assessing this guidance for future implementation.

In November 2015, the FASB issued ASU 2015-17, Income Taxes (Topic 740), Balance Sheet Classification of Deferred Taxes (“ASU 2015-15”), which eliminates the current requirement for an entity to separate deferred income taxes liabilities and assets into current and non-current amounts in a classified balance sheet. Instead, the ASU requires deferred tax liabilities, deferred tax assets and valuation allowances to be classified as non-current in a classified balance sheet. ASU 2015-17 will be effective for annual reporting periods beginning after December 15, 2016 and interim periods within those annual periods. Early adoption is permitted. Additionally, this guidance may be applied either prospectively or retrospectively to all periods presented. The Company elected not to early adopt ASU 2015-17 and is evaluating the effect of the adoption of this ASU to its condensed consolidated financial statements.

In February 2016, the FASB issued ASU No. 2016-02, Leases (“ASU 2016-02”). Under ASU 2016-02, lessees will be required to recognize the following for all leases (with the exception of short-term leases) at the commencement date: a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early application is permitted. Lessees must apply a modified retrospective transition approach for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The modified retrospective approach would not require any transition accounting for leases that expired before the earliest comparative period presented. Lessees may not apply a full retrospective transition approach. The Company is currently evaluating the impact of adopting this ASU on its condensed consolidated financial statements.

In March 2016, the FASB issued ASU No. 2016-09, Compensation – Stock Compensation (Topic 718) (“ASU 2016-09”), which simplified certain aspects of the accounting for share-based payment transactions, including income taxes, classification of awards and classification in the statement of cash flows. ASU 2016-09 will be effective for annual reporting periods beginning after December 15, 2016 and interim periods within those annual periods. The Company is currently evaluating the impact of adopting the new stock compensation standard on its consolidated financial statements.

ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses consisted of the following:

	December 31,		September 30,
		March 31,		September 30,
	2015		2015
	2016		2015
Accounts payable	$	~~193~~171,~~192~~064	$	331,355
Accrued stock payable		78,000		62,000
Accrued expenses		~~105~~196,~~957~~830		106,857
Accrued payroll		5690,~~562~~865		34,859
Total accounts payable and accrued expenses	$	~~433~~536,~~711~~759	$	535,071

DEBT OBLIGATIONS

The Company has a note payable which is due in 60 monthly installments of $489. The note matured in September 2015. As of ~~December~~March 31, ~~2015~~2016 and September 30, 2015, the balance due on this note is $3,277 of which all is current.

In August 2012, the Company borrowed $20,000. The note was originally due on December 21, 2012 but was extended to January 24, 2014. As part of the extension, the Company agreed to move $5,000 of accrued interest into the balance of the note and drop the interest rate to 1% per month. As of ~~December~~March 31, ~~2015~~2016 and September 30, 2015 the balance of this note is $25,000.

During the year ended September 30, 2012, the Company borrowed $70,000. The loan was payable on demand. The note was convertible at an amount that was less than the fair market value of the stock on the date the note was executed. This beneficial conversion feature was calculated at $25,714 and was amortized into interest expense immediately since the note was a demand note. During January 2013, the Company borrowed an additional $15,000 from the same entity and consolidated that and the previous $70,000 in loans into one promissory note in the amount of $85,000. The note was originally due in January 2014 but was extended to January 2015. The note is convertible at $0.04 per share and bears interest at 12% per annum if interest is paid in cash and 24% per annum if interest is paid in stock. The Company has the option to pay interest in shares of common stock at $0.04 per share. As of ~~December~~March 31, ~~2015~~2016 and September 30, 2015, the balance on this note is $85,000.

In July 2013, the Company borrowed $10,000. The note was due in July 2014, has an interest rate of 24% per annum if interest is paid in cash and 48% per annum if interest is paid in stock. The note is convertible at $0.04 per share. The Company has the option to pay interest on this note in stock at $0.04 per share. As of ~~December~~March 31, ~~2015~~2016 and September 30, 2015, the balance on this note is $10,000.

In September 2013, the Company borrowed $5,000. The note was due in September 2014, has an interest rate of 24% per annum if interest is paid in cash and 48% per annum if interest is paid in stock. The note is convertible at $0.04 per share. The Company has the option to pay interest on this note in stock at $0.04 per share. As of ~~December~~March 31, ~~2015~~2016 and September 30, 2015, the balance on this note is $5,000.

In May 2013, the Company borrowed $15,000. The note was originally due in November 2013 but was extended to May 2014. The note has an interest rate of 24% per annum if interest is paid in cash and 48% per annum if interest is paid in stock. The note was originally convertible at $0.04 per share but the conversion price was changed to $0.03 per share when it was extended. The Company has the option to pay interest on this note in stock at $0.04 per share. As of ~~December~~March 31, ~~2015~~2016 and September 30, 2015, the balance on this note is $15,000. As part of the extension, the Company agreed to pay a penalty of 30,000 shares of common stock for every month the loan and interest is in arrears. The estimated fair value of the shares of common stock as of ~~December~~March 31, ~~2015~~2016 is $79,~~479~~279 and is included in accounts payable and accrued expenses in the accompanying condensed consolidated balance sheet.

In April 2013, the Company borrowed $20,000. The note was due in October 2014, has an interest rate of 12% per annum if interest is paid in cash and 24% per annum if interest is paid in stock. The note is convertible at $0.05 per share. The Company has the option to pay interest on this note in stock at $0.05 per share. As of December 31, 2015 and September 30, 2015, the balance on this note is $20,000.

In March 2013, the Company borrowed $15,000. The note was due in September of 2014, has an interest rate of 12% per annum if interest is paid in cash and 24% per annum if interest is paid in stock. The note and is convertible at $0.04 per share. The Company has the option to pay interest on this note in stock at $0.04 per share. As of December 31, 2015 and September 30, 2015, the balance on this note is $15,000.

In April 2013, the Company borrowed $30,000. The note was due in October 2014, has an interest rate of 12% per annum if interest is paid in cash and 24% per annum if interest is paid in stock. The note is convertible at $0.05 per share. The Company has the option to pay interest on this note in stock at $0.05 per share. As of December 31, 2015 and September 30, 2015, the balance on this note is $30,000.

In October 2013, the Company borrowed $5,000. This note was due in August 2014, has an interest rate of 24% per annum if interest is paid in cash and 48% per annum if interest is paid in stock. The note is convertible at $0.04 per share. The Company has the option to pay interest on this note in stock at $0.04 per share. As of December 31, 2015 and September 30, 2015, the balance on this note is $5,000.

In January 2014, the Company borrowed $10,000. This note was due in February 2015, has an interest rate of 12% per annum if interest is paid in cash and 24% per annum if interest is paid in stock. The note is convertible at $0.03 per share. The Company has the option to pay interest on this note in stock at $0.03 per share. As of December 31, 2015 and September 30, 2015, the balance on this note is $10,000.

In May 2014, the Company borrowed $30,000. This note was due in May 2015 and has an interest rate of 4% per annum. During the three months ended December 31, 2015, the note was repaid through issuance of common stock, see Note 6.

In June 2014, the Company borrowed $30,000. This note was due in June 2015 and has an interest rate of 4% per annum. During the three months ended December 31, 2015, the note was repaid through issuance of common stock, see Note 6.

In July 2014, the Company borrowed $21,500. This note was due in July 2015 and has an interest rate of 4% per annum. During the three months ended December 31, 2015, the note was repaid through issuance of common stock, see Note 6.

In December 2015, the Company borrowed $13,854. This note is due in December 2019 and has an interest rate of 6% per annum if interest paid in cash and 12% per annum if interest paid in stock. The note contains a conversion feature in which it becomes convertible eighteen months subsequent to the borrowing for a conversion price of $0.016 per share. The beneficial conversion feature associated with such note is $2,511 based on the difference between the conversion price and the market price on the borrowing date, which will be recognized in earnings once the contingency is met. The note also contains an anti-dilution feature in which the conversion price would be reset in the situation where the Company has an equity issuance at a lower price than the conversion price. This feature becomes effective after the maturity date. As both the conversion feature and anti-dilution feature are contingent, no derivative liabilities or beneficial conversion features were recognized associated to this note.

As of December 31, 2015, a number of the outstanding debt obligation balances were delinquent and are classified as current in the accompanying condensed consolidated balance sheet.

As of December 31, 2015, total notes payable were $247,131, of which some are current and non-current. Interest expense related to the above notes payable was $30,753 and $12,408 for the three months ended December 31, 2015 and 2014, respectively. Accrued interest related to the above notes payable was $38,924 and $34,287 as of December 31, 2015 and September 30, 2015, respectively, included in accounts payable and accrued expenses.

6In April 2013, the Company borrowed $20,000. ~~STOCKHOLDERS’~~ The ~~DEFICIT~~note was due in October 2014, has an interest rate of 12% per annum if interest is paid in cash and 24% per annum if interest is paid in stock. The note is convertible at $0.05 per share. The Company has the option to pay interest on this note in stock at $0.05 per share. As of March 31, 2016 and September 30, 2015, the balance on this note is $20,000.

In March 2013, the Company borrowed $15,000. The note was due in September of 2014, has an interest rate of 12% per annum if interest is paid in cash and 24% per annum if interest is paid in stock. The note and is convertible at $0.04 per share. The Company has the option to pay interest on this note in stock at $0.04 per share. As of March 31, 2016 and September 30, 2015, the balance on this note is $15,000.

In April 2013, the Company borrowed $30,000. The note was due in October 2014, has an interest rate of 12% per annum if interest is paid in cash and 24% per annum if interest is paid in stock. The note is convertible at $0.05 per share. The Company has the option to pay interest on this note in stock at $0.05 per share. As of March 31, 2016 and September 30, 2015, the balance on this note is $30,000.

In October 2013, the Company borrowed $5,000. This note was due in August 2014, has an interest rate of 24% per annum if interest is paid in cash and 48% per annum if interest is paid in stock. The note is convertible at $0.04 per share. The Company has the option to pay interest on this note in stock at $0.04 per share. As of March 31, 2016 and September 30, 2015, the balance on this note is $5,000.

In January 2014, the Company borrowed $10,000. This note was due in February 2015, has an interest rate of 12% per annum if interest is paid in cash and 24% per annum if interest is paid in stock. The note is convertible at $0.03 per share. The Company has the option to pay interest on this note in stock at $0.03 per share. As of March 31, 2016 and September 30, 2015, the balance on this note is $10,000.

As of March 31, 2016, a number of the outstanding debt obligation balances were delinquent and are classified as current in the accompanying condensed consolidated balance sheet.

As of March 31, 2016, total notes payable were $247,131, of which some are current and non-current. Interest expense related to the above notes payable was $30,753 and $12,408 for the three months ended December 31, 2015 and 2014, respectively. Accrued interest related to the above notes payable was $38,924 and $34,287 as of March 31, 2016 and September 30, 2015, respectively, included in accounts payable and accrued expenses.

STOCKHOLDERS’ DEFICIT

Common Stock:

In ~~November~~January ~~and December 2015~~2016, the Company issued 1469,~~243,243~~388 shares of common stock as compensation for a total expense of $2311,000, 1,040,541 shares for services valued at $25,000, 5,553,131 shares for interest and repayments of debt obligations valued at $121,834, 7,660,562 shares issued for cash proceeds of $137,890 and 3,735,294 shares for repayments of liabilities valued at $63,500.

During the three months ended December 31, 2015, the Company agreed to issue 1,000,000 shares of common stock valued at $18,000 that had not been issued to and accordingly, the unissued shares have been reflected as common stock subscribed but unissued in the accompanying condensed consolidated balance sheet as of December 31, 2015. The shares of common stock were issued in April 2015.

During the three months ended December 31, 2015, the Company issued a total of 28,059,574 shares of common stock for shares that were previously classified as common stock subscribed but unissued totaling $519,594.

COMMITMENTS AND CONTINGENCIES

Legal Matters

In the normal course of business, the Company periodically becomes involved in litigation. As of ~~December~~March 31, ~~2015~~2016, in the opinion of management, the Company had no pending litigation that would have a material adverse effect on the Company's condensed consolidated financial position, results of operations, or cash flows.

Indemnities and Guarantees

The Company has made certain indemnities and guarantees, under which it may be required to make payments to a guaranteed or indemnified party, in relation to certain actions or transactions. The Company indemnifies its directors, officers, employees and agents, as permitted under the laws of the State of Nevada. In connection with its facility leases, the Company has agreed to indemnify its lessors for certain claims arising from the use of the facilities. The duration of the guarantees and indemnities varies, and is generally tied to the life of the agreement. These guarantees and indemnities do not provide for any limitation of the maximum potential future payments the Company could be obligated to make. Historically, the Company has not been obligated nor incurred any payments for these obligations and, therefore, no liabilities have been recorded for these indemnities and guarantees in the accompanying condensed consolidated balance sheets.

RELATED PARTY TRANSACTIONS

As of ~~December~~March 31, ~~2015~~2016 and September 30, 2015 the accounts payable balance due to Chamberlain Capital Partners (“Chamberlain”), a company owned by Jack Lennon, former president of the Company is $10,000.

SUBSEQUENT EVENTS

The Company has evaluated subsequent events through filing date of this Form 10-Q, and have determined that no subsequent events have occurred that would require recognition in the condensed consolidated financial statements or disclosure in the notes thereto other then as discussed herein and in the accompanying notes.

From ~~January~~April 1, 2016 through the filing date of this Form 10-Q, the Company issued 1,~~000~~433,~~000~~962 ~~and 903,350~~ shares of common stock in connection with ~~a stock subscription agreement and as~~ compensations for services, ~~respectively~~and subscription agreement.

1213

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion and analysis provides information to explain our results of operations and financial condition. You should also read our unaudited interim condensed consolidated financial statements and their notes included in this Form 10-Q, and our audited consolidated financial statements and their notes, Risk Factors and other information included in our Annual Report on Form 10-K for the year ended September 30, 2015. This report contains forward-looking statements. Forward-looking statements within this Form 10-Q are identified by words such as “believes,” “anticipates,” “expects,” “intends,” “may,” “will” “plans” and other similar expressions, however, these words are not the exclusive means of identifying such statements. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements are subject to significant risks, uncertainties and other factors, which may cause actual results to differ materially from those expressed in, or implied by, these forward-looking statements. Except as expressly required by the federal securities laws, we undertake no obligation to publicly update or revise any forward-looking statements to reflect events, circumstances or developments occurring subsequent to the filing of this Form 10-Q with the U.S. Securities and Exchange Commission and you should not place undue reliance on these forward-looking statements. You should carefully review and consider the various disclosures the Company makes in this report and our other reports filed with the U.S. Securities and Exchange Commission that attempt to advise interested parties of the risks, uncertainties and other factors that may affect our business.

Background

We were organized under the laws of the State of Nevada on April 4, 2006 under the name “Northwest Chariots, Inc.” and were engaged in the business of renting and selling electrically powered human transporters, like electric bicycles, chariots and quads. Subsequent to our fiscal year ended September 30, 2009, we decided to change our product mix to air purification products and to focus on the research, development, manufacturing and sales of air purification systems and products.

In furtherance of our business objectives, on November 12, 2009, we affected a 32-for-1 forward stock split of all our issued and outstanding shares of common stock, and we merged with our wholly-owned subsidiary, UV Flu Technologies, Inc., for the purposes of effecting a name change to “UV Flu Technologies, Inc.”

Effective November 15, 2009, we acquired AmAirapure Inc.’s air purification technology, product, inventory, and certain equipment pursuant to an Asset Purchase Agreement with AmAirapure, Inc. We issued 15,000,000 shares of our common stock to shareholders of AmAirapure in connection with the asset acquisition. Additionally, on November 25, 2009, we entered into a Distribution Agreement with Puravair Distributors LLC (“Puravair”) where we appointed Puravair as our exclusive master distributor for our Viratech UV-400 product and our other products for the professional, medical, and commercial markets in the U.S. and Canada. On September 30, 2010, we terminated our Distribution Agreement with Puravair and began adding new distributors, which totaled six as of December 31, 2014.

The latest production runs of our Viratech UV-400 product incorporate our patented UV bacteria killing technology, which has been cleared by the FDA for use as a medical device. In June 2010, we expanded our market reach by introducing the latest generation of our Viratech UV-400 product into the residential and hospitality markets.

On October 28, 2010, we entered into a binding letter of intent with The Red Oak Trust (“Red Oak”) (the “LOI”) in connection with our proposed acquisition of one hundred percent (100%) of the issued and outstanding units of RxAir Industries, LLC, a Nevada limited liability company (“RxAir”), which is wholly owned by Red Oak (the “Acquisition”). At the closing of the Acquisition, Rx Air became a wholly-owned subsidiary of the Company. The acquisition was consummated January 24, 2011.

On January 31, 2011, we entered into and completed our Acquisition of RxAir pursuant to the Acquisition Agreement, dated January 31, 2011, by the Company, and Red Oak, as the sole shareholder of RxAir. At the closing of the Acquisition, RxAir became a wholly-owned subsidiary of the Company.

We currently have limited revenues from operations. In order to meet our business objectives, we will need to raise additional funds through equity or debt financing. There can be no assurance that we will be successful in raising additional funds and, if unsuccessful, our plans for expanding operations and business activities may have to be curtailed. Any attempt to raise funds, through debt or equity financing, would likely result in dilution to existing shareholders.

Results of Operations

The following discussion of the financial condition, results of operations, cash flows and changes in our financial position should be read in conjunction with our audited consolidated financial statements and notes included in our Annual Report on Form 10-K for the fiscal year ended September 30, 2015 filed on March 28, 2016.

~~Three months ended December 31, 2015 as compared to the three months ended December 31, 2014~~14

Three and six months ended March 31, 2016 as compared to the three and six months ended March 31, 2015

Net Sales

Net Sales for the three months ended March 31, 2016, were $52,576, a decrease of $12,884 over the same three month period in 2015. The sales ~~increase~~decrease is primarily related to the relationship with a distributor that has placed the product on Amazon.com. The results do not fully reflect the efforts being made toward sales in other markets such as medical/health, commercial and retail.

~~The~~During ~~Company~~the issix ~~actively~~months ~~seeking~~ended ~~mediums~~March ~~that~~31, ~~efficiently~~2016, ~~sell~~we ~~products~~recognized ~~such~~net assales ~~marketing/rep~~of ~~firms~~$119,627 ~~and~~as ~~distributors~~compared to $100,393 for the ~~above~~six ~~mentioned~~months ~~markets.~~ended WeMarch ~~are~~31, ~~constantly~~2015, ~~striving~~an toincrease ~~improve~~of ~~our~~$19,234, as ~~retail~~sales ~~presents~~in asnew ~~well~~markets opened in FY 2016.

The Company is actively seeking mediums that efficiently sell products such as marketing/rep firms and distributors for the above mentioned markets. We are constantly striving to improve our retail presence as well.

We are working on a HEPA unit which would target the allergy and asthma segment of health market and all the parts of the world that have PM 2.5 (air pollution issues), such as Asia.

Gross Profit

Gross Profit for the three months ended March 31, 2016, was $26,049, an increase of $9,827 over the same three month period in 2015. The increase is primarily due to the decrease cost of sales because of lower cost of units.

During the six months ended March 31, 2016, we recognized gross profit of $55,504 as compared to $25,853 for the six months ended March 31, 2015, an increase of $29,651, due to decrease cost of sales because of lower cost of units.

General and Administrative Expenses

During the three months ended ~~December~~March 31, ~~2015~~2016, the Company incurred general and administrative expenses of $~~171~~115,~~163~~324 as compared to $~~377~~136,~~941~~495 for the three months ended ~~December~~March 31, ~~2014~~2015, a decrease of $21,171, as shown below:

		Three months ended
	December 31, 2015		December 31, 2014
	March 31, 2016		March 31, 2015
Marketing	$	-29	$	~~63,672~~-
Office and administration		~~122~~57,~~760~~600		~~222~~120,~~262~~690
Professional and consulting fees		4655,~~387~~678		8713,~~132~~963
Depreciation		2,~~016~~017		41,~~875~~842
Total	$	~~171~~115,~~163~~324	$	~~377~~136,~~941~~495

~~General~~During ~~and~~the ~~administrative~~six ~~expenses~~months ~~decreased~~ended byMarch ~~$206~~31,~~778~~ ~~from $377~~2016,~~941~~ ~~for~~ the ~~three~~Company ~~months~~incurred ~~ended~~general ~~December~~and 31administrative expenses of $286,485 ~~2014~~as compared to $~~171~~514,~~163~~436 for the ~~three~~six months ended ~~December~~March 31, 2015., ~~The decrease was the result of~~ a decrease ~~in marketing expense primarily related to the development~~ of a$227,951 ~~new~~as ~~website~~shown and the rebranding effort from UV Flu to RxAir. The decrease is also attributable to a decrease in office and administrative expenses primarily related to closing of the RxAir factory. The decrease in professional and consulting expenses is primarily related to the reduction of our demand for outside services.below:


		Six months ended
	March 31, 2016		March 31, 2015
Marketing	$	29	$	63,672
Office and administration		180,360		342,952
Professional and consulting fees		102,063		101,095
Depreciation		4,033		6,717
Total	$	286,485	$	514,436

The decrease for both periods was the result of a decrease in marketing expense primarily related to the development of a new website and the rebranding effort from UV Flu to RxAir. The decrease is also attributable to a decrease in office and administrative expenses primarily related to closing of the RxAir factory.

Other Income (Expenses), net

The ~~change~~small decrease in other income (expense) net of $470 for the three months ended March 31, ~~during~~2016 compared to the ~~current~~three ~~period~~months ended March 31, 2015 is due to the ~~$30,753~~decrease ofin interest expense. Other income (expense) net for the ~~three~~six months ended ~~December~~March 31, ~~2015~~2016 was ($57,010) compared to $4,388 for the ~~interest~~same ~~expense~~six month period in 2015, a decrease of $1261,~~408~~378. The ~~and~~decrease ~~gain~~in onother income (expense) net is due to the $17,875 decrease in interest expense and the change in fair value of derivative liabilities of $43,503 reported for the ~~three~~six months ended ~~December~~March 31, ~~2014~~2015.

Net Loss

For the three months ended ~~December~~March 31, 2016 and March 31, 2015, we incurred a net loss of $115,532 and ~~December~~$147,000, respectively. For the six months ended March 31, ~~2014~~2016 and March 31, 2015, we incurred a net loss of $~~172~~287,~~461~~991 and $~~337~~484,215 respectively.

Liquidity and Capital Resources

As of ~~December~~March 31, ~~2015~~2016, we had cash of $213,~~238~~282, and negative working capital of $~~(480~~582,~~510)~~522. In order to survive, we are dependent on increasing our sales volume. Additionally, we plan to continue further financings and believe that this will provide sufficient working capital to fund our operations for at least the next 12 months. Changes in our operating plans, increased expenses, additional acquisitions, or other events may cause us to seek additional equity or debt financing in the future. The Company’s unaudited condensed consolidated financial statements are prepared using the accrual method of accounting in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities in the normal course of business.

The ~~following~~Company’s isunaudited acondensed ~~summary~~consolidated offinancial statements are prepared using the ~~Company's~~accrual ~~cash~~method ~~flows~~of ~~provided~~accounting byin ~~(used~~accordance with accounting principles generally accepted in the United States of America (“GAAP”) ~~operating,~~and ~~investing~~have been prepared on a going concern basis, ~~and~~which ~~financing~~contemplates ~~activities~~the ~~for~~realization of assets and the ~~three~~settlement ~~months~~of ~~ended~~liabilities ~~December~~in ~~31,~~the ~~2015~~normal ~~and~~course ~~2014:~~of business.

	For the three months ended
		December 31, 2015		December 31, 2014
Net cash used in operating activities	$	(161,293)	$	(4,268)
Net cash provided by (used in) financing activities		169,744		(363)
Net change in cash		8,451		(4,631)
Cash, beginning		12,787		4,748
Cash, ending	$	21,238	$	117

The following is a summary of the Company's cash flows (used in) provided by operating, investing, and financing activities for the six months ended March 31, 2016 and 2015:


	For the six months ended
		March 31, 2016		March 31, 2015

Net cash used in operating activities	$	(179,249)	$	(1,831)
Net cash provided by (used in) financing activities		169,744		(363)
Net change in cash		(9,505)		(2,194)
Cash, beginning		12,787		4,748
Cash, ending	$	3,282	$	2,554

We anticipate that our cash requirements will be significant in the near term due to contemplated development, purchasing, marketing and sales of our air purification technologies and products. Accordingly, we expect to continue to raise capital through share offering and sales to fund current operations.

Going Concern

The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As shown in the accompanying consolidated financial statements, the Company has negative working capital and has incurred operating losses in all periods presented. These factors raise substantial doubt about the Company’s ability to continue as a going concern.

The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be necessary in the event that the Company cannot continue as a going concern. Management anticipates that it will be able to raise additional working capital through the issuance of stock and through additional loans from investors.

The ability of the Company to continue as a going concern is dependent upon the Company’s ability to attain a satisfactory level of profitability and obtain suitable and adequate financing. There can be no assurance that management’s plan will be successful.

Recent Accounting Pronouncements

The Company does not expect the adoption of recently issued accounting pronouncements to have a significant impact on the Company’s results of operations, financial position or cash flows.

Critical Accounting Policies

Critical accounting policies are defined as those that are reflective of significant judgments and uncertainties, and potentially result in materially different results under different assumptions and conditions. We believe that our critical accounting policies are limited to those described in Critical Accounting Policies section of Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the fiscal year ended September 30, 2015.

Off-Balance Sheet Arrangements

None.

Capital Expenditures

None.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

As a smaller reporting company, we are not required to provide this information.

Item 4. Controls and Procedures.

Under the supervision of and with the participation of our management, including the Company’s Principal Executive Officer/Principal Financial Officer, we evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this report. Based upon that evaluation, our Principal Executive Officer /Principal Financial Officer concluded that our disclosure controls and procedures were not effective.

During the ~~three~~six months ended ~~December~~March 31, ~~2015~~2016, management determined that we had material weaknesses relating to the segregation of duties within our accounting functions and our quarterly and annual financial close processes. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of a Company’s annual or interim financial statements will not be prevented or detected on a timely basis. Because these material weaknesses as to internal control over financial reporting also bear upon our disclosure controls and procedures, our Principal Executive Officer /Principal Financial Officer concluded that our disclosure controls and procedures were not effective.

Despite the conclusion that disclosure controls and procedures were not effective as of the end of the period covered by this report, the Principal Executive Officer /Principal Financial Officer believes that the consolidated financial statements and other information contained in this quarterly report present fairly, in all material respects, our business, financial condition and results of operations.

Internal Control over Financial Reporting

There were no changes in our internal controls over financial reporting during the period covered by this report that have materially affected or are reasonably likely to materially affect our internal controls over financial reporting.

We are currently taking steps to both remedy the material weaknesses described above and facilitate our management’s assessment of internal control over financial reporting in accordance with the Sarbanes-Oxley Act and Commission rules. Our planned steps include:

We have engaged additional expertise to assist us with our financial reporting and accounting processes;

We consolidated our accounting books and records to provide for a single process for preparing our financial reports; and

We have entered into a relationship with a new warehousing company which provides for enhanced and efficient reporting on sales and inventory.

1617

PART II—OTHER INFORMATION

Item 1. Legal Proceedings.

None.

Item 1A. Risk Factors.

Not applicable.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

During the three months ended ~~December~~March 31, ~~2015~~2016, the Company issued 47469,~~292,345~~388 shares of its common stock.

No underwriters were involved in any of the issuances provided in this Item 2. The shares were issued pursuant to Section 4(2) of the Securities Act of 1933, as amended (the “Act”) because the individuals either represented that they were “accredited investors” as such term is defined in the rules and regulations promulgated under the Securities Act or were employees of the Company and were in possession of the information that registration of the securities would provide them. The sale of the securities did not involve any form of general solicitation or general advertising.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

None.

Item 5. Other Information.

None

Item 6. Exhibits.

LIST OF EXHIBITS


Exhibit No.		Description

31.1		PEO Certification required under Section 302 of Sarbanes-Oxley Act of 2002
31.2		PFO Certification required under Section 302 of Sarbanes-Oxley Act of 2002
32		PEO/PFO Certification required under Section 906 of Sarbanes-Oxley Act of 2002
101.INS		XBRL Instance Document (furnished herewith)
101.SCH		XBRL Taxonomy Extension Schema (furnished herewith)
101.CAL		XBRL Taxonomy Extension Calculation Linkbase (furnished herewith)
101.DEF		XBRL Taxonomy Extension Definition Linkbase (furnished herewith)
101.LAB		XBRL Taxonomy Extension Label Linkbase (furnished herewith)
101.PRE		XBRL Taxonomy Extension Presentation Linkbase (furnished herewith)

1718

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	UV FLU TECHNOLOGIES, INC
Date: May 18, 2016	By:	/s/ Michael S. Ross
Date: June 17, 2016	By:	/s/ Michael S. Ross
	Name:	Michael S. Ross
	Title:	President, Chief Executive Officer andChief Financial Officer

1819

Filing Compare · UV FLU TECHNOLOGIES INC